Information for the public Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (PDF 65 KB) Published: 26 August 2009 Gwybodaeth i'r cyhoedd (Word 241 KB) Published: 16 November 2009
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (PDF 65 KB) Published: 26 August 2009